Aquestive Therapeutics (AQST) Scheduled to Post Quarterly Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST) will release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Aquestive Therapeutics to post earnings of ($0.09) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The company had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $11.79 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aquestive Therapeutics Stock Performance

NASDAQ AQST traded down $0.18 during trading hours on Tuesday, hitting $3.56. 907,195 shares of the company traded hands, compared to its average volume of 2,246,851. The business’s 50-day moving average is $4.19 and its 200-day moving average is $2.84. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23. The stock has a market capitalization of $260.95 million, a price-to-earnings ratio of -26.68 and a beta of 2.87.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday. JMP Securities increased their price target on Aquestive Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Friday, March 15th. Raymond James assumed coverage on Aquestive Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, Piper Sandler began coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They set an “overweight” rating and a $10.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Aquestive Therapeutics has an average rating of “Buy” and an average price target of $8.00.

Insider Buying and Selling

In related news, insider Alexander Mark Schobel sold 25,000 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $5.19, for a total value of $129,750.00. Following the sale, the insider now directly owns 1,040,371 shares of the company’s stock, valued at $5,399,525.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 8.39% of the stock is owned by company insiders.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.